Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.58 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227976 | 1.00 | BCAT2 (0.67) | BCAT2MKNK1MKNK2PKN1PKN2 | |
| SCHEMBL30514275 | 1.00 | BCAT2 (0.67) | BCAT2MKNK1MKNK2PKN1PKN2 | |
| Hydrochloric Acid SCHEMBL27890957 | 0.98 | BCAT2 (0.65) | BCAT2MKNK1MKNK2PKN1PKN2 | |
| Hydrochloric Acid SCHEMBL30165666 | 0.98 | BCAT2 (0.65) | BCAT2MKNK1MKNK2PKN1PKN2 | |
| Pyrrole SCHEMBL28144303 | 0.91 | BCAT2 (0.56) | BCAT2MKNK1MKNK2PKN1PKN2 | |
| SCHEMBL30263343 | 0.86 | CYP19A1 (0.63) | MKNK1MKNK2 | |
| Pyridine SCHEMBL28666919 | 0.86 | BCAT2 (0.79) | BCAT2KMT2AHTTPARP1 | |
| SCHEMBL28019336 | 0.86 | MKNK1 (0.58) | MKNK1MKNK2PKN1PKN2F7 | |
| SCHEMBL10968862 | 0.85 | HTT (0.54) | BCAT2MKNK1MKNK2SIRT3KMT2A | |
| SCHEMBL17591715 | 0.85 | MKNK1 (0.54) | BCAT2MKNK1MKNK2PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| EP-3259256-A1 | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CN) | 2017-12-27 | — | — | EP | claimed |
| WO-2016131192-A1 | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-08-25 | — | — | WO | claimed |
| JP-2011510632-A | — | — | 2011-04-07 | — | — | JP | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| WO-2025151311-A1 | NICOTINAMIDE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-111989328-B | Heterocyclic derivatives as pest control agents | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| CN-101272685-A | Diarylamine-containing compounds and compositions, and their use as modulators of C-KIT receptors | IRM LLC (BM) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1115334-C | Pyridine derivative and medicine containing the same | OTSUKA PHARMA CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
| CN-1294581-A | Pyridine derivative and pharmaceutical contg. same | OTSUKA PHARMA CO LTD (JP) | 2001-05-09 | — | — | CN | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | BCAT2 870/4885MKNK1 4163/4885MKNK2 4412/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | BCAT2 2558/4885MKNK1 4463/4885MKNK2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.